EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies

Nana A Mensah iD, Michael J Fassett iD, Nehaa Khadka iD, Jiaxiao M Shi iD, Fagen Xie iD, Vicki Y Chiu iD, Theresa M Im iD, Sunhea Kim iD, Daniella Park iD, Carol Mao iD, Matthew Molaei iD, Iris Lin iD und 1 weitere

JMIR Research Protocols · 2025

DOI: 10.2196/77836 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Nana A Mensah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Hauptthemen laut MEDLINE: Erythroblastosis, Fetal. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed.

Objective

This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system.

Methods

We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processing–assisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status.

Results

The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse.

Conclusions

We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processing–assisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. International Registered Report Identifier (IRRID) DERR1-10.2196/77836

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythroblastosis, FetalHumansFemalePregnancyInfant, NewbornRetrospective StudiesAdultFeasibility StudiesCaliforniaPregnancy OutcomeObservational Studies as Topic

Stichwörter der Autor:innen

HDFNelectronic health recordepidemiologyfetushemolytic diseasehemolytic disease of the fetus and newbornnewbornprotocoltreatment use

Autor:innen und Institutionen

  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.
  • Department of Obstetrics & Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, CA, United States.
  • Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States.
  • Johnson & Johnson, Horsham, PA, United States.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States.

ORCID-Profile: Nana A Mensah, Michael J Fassett, Nehaa Khadka, Jiaxiao M Shi, Fagen Xie, Vicki Y Chiu, Theresa M Im, Sunhea Kim, Daniella Park, Carol Mao, Matthew Molaei, Iris Lin, Darios Getahun

Zitieren

APA

Mensah, N. A., Fassett, M. J., Khadka, N., Shi, J. M., Xie, F., Chiu, V. Y., Im, T. M., Kim, S., Park, D., Mao, C., Molaei, M., Lin, I., & Getahun, D. (2025). Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. JMIR Research Protocols. https://doi.org/10.2196/77836

Vancouver

Mensah NA, Fassett MJ, Khadka N, Shi JM, Xie F, Chiu VY, et al. Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. JMIR Research Protocols. 2025. doi:10.2196/77836

BibTeX
@article{Mensah2025,
  author = {Mensah, Nana A and Fassett, Michael J and Khadka, Nehaa and Shi, Jiaxiao M and Xie, Fagen and Chiu, Vicki Y and Im, Theresa M and Kim, Sunhea and Park, Daniella and Mao, Carol and Molaei, Matthew and Lin, Iris and Getahun, Darios},
  title = {Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/77836}
}
Kostenlos starten →